Clinical Trials
7
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:3
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 1
3 (42.9%)A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06505928
- Locations
- 🇲🇳
National cancer canter of Monglia, Ulaanbaatar, Mongolia
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
Phase 2
Completed
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Drug: Hepalatide Placebo
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05827146
- Locations
- 🇨🇳
The first affiliated hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
🇨🇳The first hospital of Jilin University, Changchun, China
🇲🇳the National cancer center of Mongolia, Ulaanbaatar, Mongolia
A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
Phase 2
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Placebo of HepalatideDrug: Pegylated Interferon alfa 2a
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05244057
- Locations
- 🇨🇳
Shanghai Tong Ren Hospital, Shanghai, Shanghai, China
A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Registration Number
- NCT04662164
A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Hepalatide 4.2mgDrug: Hepalatide 2.1mgDrug: Hepalatide 6.3mgDrug: placebo 2.1mgDrug: Pegylated InterferonDrug: placebo 4.2mgDrug: placebo 6.3mg
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04426968
- Locations
- 🇨🇳
The fifth medical center of PLA, Beijing, Beijing, China
🇨🇳Jilin Hepatobiliary Disease Hospital, Changchun, China
🇨🇳The first hospital of Jilin University, Changchun, China
- Prev
- 1
- 2
- Next
News
No news found